Lacosamide Market : Global Industry Analysis and Opportunity Assessment, 2036

How big is the lacosamide market in 2026?

USD 1100.2 million in 2026 and USD 1890.2 million by 2036 at a 5.6% CAGR.

The lacosamide market is projected to grow from USD 1034.9 million in 2025 to USD 1890.2 million by 2036 at 5.6% CAGR. Demand is concentrated in regulated generic epilepsy products and supplier qualification for antiepileptic drug. Powder is forecast to hold 62.4% share in 2026 with easier tablet blending and oral solution processing.

Summary of the Lacosamide Market

Market Signal	Commercial Impact
Demand and Growth Drivers	Lacosamide API demand is supported by rising generic epilepsy treatment and expanding formulation requirements. Chronic epilepsy treatment demand and wider generic product availability continue to reinforce long-term API consumption. Growth is driven by partial-onset seizure therapies requiring repeat API supply for approved medicines. Direct supplier contracts are gaining importance as formulation companies seek audit access and change-control support. Injectable and oral solution formulations are expanding API qualification requirements beyond conventional tablet production.
Product and Segment View	Powder APIs, high-purity grades, and partial-onset seizure applications dominate the market. Powder is projected to account for 62.4% of the 2026 market (by form), supported by consistent blending performance and predictable dissolution. ≥99.5% purity grade is estimated to hold 54.8% of the 2026 market (by purity), reflecting stricter impurity requirements in regulated markets. Partial-onset seizures are forecast to represent 66.3% of the 2026 market (by application), aligned with the primary approved therapeutic indication. Direct sales are anticipated to secure 58.1% of the 2026 market (by sales channel), driven by audit access and Drug Master File (DMF) support.
Geography and Growth Outlook	North America, Europe, and India remain key markets for lacosamide API. North America is projected to account for 34.2% of the 2026 market (by region), supported by strong USA generic product activity. Europe is anticipated to hold 25.4% of the 2026 market (by region), driven by reimbursement systems and regulated pharmacy supply. India is forecast to grow at a 6.7% CAGR (2026–2036), supported by expanding formulation manufacturing and API production capabilities.
Competitive Landscape	Competition is focused on regulatory compliance, API manufacturing expertise, and formulation integration. MSN Laboratories and Cambrex compete through proven API manufacturing capabilities and regulatory support. Aurobindo and Dr. Reddy's strengthen market presence through integrated finished-dose manufacturing and API supply.
Analyst Perspective	Lacosamide API has evolved into a quality-driven generic market where regulatory performance is a key competitive advantage. Buyers prioritize impurity control, inspection history, and regulatory compliance alongside production capacity. Suppliers are increasingly expected to support multiple dosage forms, including tablets, oral solutions, and injectable formulations. Manufacturers with strong DMF documentation and validated quality systems are better positioned to secure long-term supply contracts. — Anurag Sharma, Principal Analyst, Future Market Insights

Quality control is the main pressure point for lacosamide API buyers. The World Health Organization reported in February 2024 that epilepsy affects around 50 million people worldwide. The same source states that up to 70% of people living with epilepsy could become seizure free with appropriate antiseizure medicines. FDA analysis published in September 2024 showed first generic lacosamide tablets delivered USD 2,246 million in estimated first-year savings after 2022 approvals. That price reset widens access but forces API suppliers to win on impurity control and batch consistency.

The lacosamide market is projected to expand through regulated generic medicine channels and approved epilepsy dosage forms. Buyers assess API suppliers on purity records and drug master file support before price negotiation.

Which factors support expansion in the lacosamide market?

Generic product economics and dosage-form breadth support market value across regulated epilepsy treatment channels.

• Market value is reinforced by finished-dose product approvals and API qualification across multiple dosage forms.
• Supplier pricing reflects synthesis yield and residual solvent control before commercial negotiation starts. Documentation strength adds a second buyer filter.
• Revenue improves for API suppliers that help formulation buyers reduce filing risk during source changes.
• Buyer trust rises with impurity trend data and quick responses to regulator questions.

Why is the lacosamide market growing?

Growing seizure treatment demand and broader dosage-form adoption are sustaining growth in the lacosamide market.

Adult and pediatric seizure treatment needs are projected to keep lacosamide relevant within anticonvulsant therapy. DailyMed states that lacosamide tablets treat partial-onset seizures in patients one month of age and older. It also lists adjunctive therapy for primary generalized tonic-clonic seizures in patients four years of age and older.

Generic entry changed lacosamide from a high-price branded product input into a cost-sensitive small molecule API opportunity. FDA analysis showed lacosamide tablet prices fell 92% after first generic approval. That improves treatment access and pushes API vendors to protect margin through fewer batch failures.

Dosage-form spread is another factor driving market growth. DailyMed notes that lacosamide injection may be used during periods in which oral administration is temporarily not feasible. This reinforces the commercial case for injectable drug production support and gives buyers a reason to test particle control and impurity records before qualification.

How is the lacosamide market segmented?

The lacosamide industry is segmented by form, purity grade, application, sales channel, and region.

• Powder is projected to secure 62.4% share in 2026 through tablet blending and oral solution handling.
• The ≥99.5% grade is anticipated to hold 54.8% share in 2026 with buyer focus on impurity control.
• Partial-onset seizures are projected to account for 66.3% share in 2026 through the principal approved use.
• Direct sales are forecast to represent 58.1% share in 2026, shaped by audit access and regulatory document needs.

Which form category holds a notable share in the lacosamide market?

• Powder is projected to account for 62.4% share in 2026, with formulators favoring simpler blending and scale-up handling.
• Crystalline API remains relevant for buyers that need tighter solid-state control and polymorph consistency.

How does the purity grade segment perform in the lacosamide market?

• The ≥99.5% grade is estimated to hold 54.8% share in 2026 with stronger impurity and residual solvent expectations.
• Mid-purity grades serve buyers with less demanding dossiers, but export-facing firms usually require stronger quality evidence.

What drives demand across application options in the lacosamide market?

• Partial-onset seizures are projected to lead application demand in 2026, guided by the core approved indication.
• Adjunctive epilepsy therapy supports added volume in patients needing combination treatment for seizure control.

How are buyers selecting across sales channels in the lacosamide market?

• Direct sales are anticipated to lead in 2026 through audit access and drug master file communication.
• Distributors serve smaller buyers that need API availability but may not manage full supplier qualification directly.

What are the driver, restraints, and opportunities in the lacosamide market?

Generic epilepsy demand supports growth. Price erosion and supplier qualification burden limit margin upside.

• Driver: Generic product expansion increases API volume needs across oral and injectable lacosamide formats.
• Restraint: Price erosion limits supplier margin flexibility after finished-dose competition expands.
• Opportunity: High-purity API suppliers can win by pairing cost discipline with regulator-ready impurity files.

Lacosamide API Demand Outlook

Demand outlook is moving toward qualified suppliers that can support multiple dosage forms without separate documentation failures. FDA analysis reported USD 2,246 million in estimated first-year savings from lacosamide tablets after 2022 approvals. This expands the buyer pool for generic products but keeps pricing discipline high. Suppliers serving specialty API sourcing must therefore show evidence depth before they compete on cost.

Dosage-Form Qualification Analysis

Qualification pressure differs across oral and injectable formats. DailyMed states that lacosamide injection can be used during periods in which oral administration is temporarily not feasible. Injectable use raises supplier expectations with sterile routes depending on tighter impurity and compatibility controls. This creates a practical opening for API vendors with injectable drug delivery requirements.

Which countries are growing fastest in the lacosamide market?

India 6.7% CAGR, China 6.2% CAGR, United States 5.2% CAGR, South Korea 5.0% CAGR, Germany 4.9% CAGR, United Kingdom 4.8% CAGR, France 4.6% CAGR, and Japan 4.4% CAGR through 2036.

Country	CAGR
India	6.7%
China	6.2%
United States	5.2%
South Korea	5.0%
Germany	4.9%
United Kingdom	4.8%
France	4.6%
Japan	4.4%

Source: Future Market Insights, 2026.

How do country-level CAGRs compare in the lacosamide market?

India records the most notable selected-country growth profile and Japan shows the most cautious expansion outlook.

• India is forecast to record 6.7% CAGR by 2036, with formulation approvals and API supply depth.
• China is forecast to record 6.2% CAGR by 2036, through supply diversification and export certificate clarity.
• United States is forecast to record 5.2% CAGR by 2036, with ANDA activity and product-listing visibility.
• South Korea is forecast to record 5.0% CAGR by 2036, guided by reimbursement control and MFDS review discipline.
• Germany is forecast to record 4.9% CAGR by 2036, shaped by tender pressure and supply continuity needs.
• United Kingdom is forecast to record 4.8% CAGR by 2036, through oral liquid authorization and NHS channel discipline.
• France is forecast to record 4.6% CAGR by 2036, influenced by generic substitution and regulator scrutiny.
• Japan is forecast to record 4.4% CAGR by 2036, tied to conservative source switching and documentation expectations.

How fast is the lacosamide market growing in India?

A 6.7% CAGR through 2036 reflects formulation approvals and export-ready API supply depth.

Country Market Snapshot Table

Parameter	Value
Market Size in 2025 (Value)	USD 95.6 million
Market Size in 2026 (Value)	USD 102.0 million
Market Forecast in 2036 (Value)	USD 195.1 million
CAGR (2026 to 2036)	6.7%
Years Considered	2021 to 2036
Base Year	2025
Forecast Period	2026 to 2036
Units Considered	Value (USD million)
Leading Sub-Region	Hyderabad, Ahmedabad, and western formulation clusters

India Lacosamide Market Outlook

• India is a dual-role market for lacosamide API with local formulation activity and export supply shaping demand. Domestic buyers evaluate API sources against CDSCO expectations and export customers still require clean audit files.
• Formulation companies are projected to widen oral and injectable options through 2036. API suppliers with validated impurity controls and responsive documentation teams should secure deeper buyer confidence.

Key Growth Drivers

• Local formulation activity supports demand for qualified domestic API sources. CDSCO recommended permission for lacosamide injection at 1 mg/mL.
• Sustained-release development adds a differentiated oral route for formulators. CDSCO accepted Eris Lifesciences' bioequivalence study report in 2026.
• API manufacturing depth gives export buyers more supplier options than smaller regulated markets.
• Direct buyer audits improve confidence in suppliers that maintain batch records and change-control files.

Key Restraints

• Bioequivalence review can slow launch timing for new strengths and modified-release formats.
• Export buyers still require strict audit evidence before long-term contracts are signed.
• CDSCO committee review can extend timelines for submissions that need added clinical or formulation evidence.

What makes India unique

India is differentiated by domestic dosage-form growth and supplier depth for global API programs.

Key Companies

• MSN Laboratories
• Rakshit Drugs
• SNJ Labs
• Intas Pharmaceuticals
• Torrent Pharmaceuticals
• Aurobindo Pharma
• Dr. Reddy’s Laboratories

Sales & Marketing Channels

• Direct API sales
• Domestic formulation contracts
• Export API contracts
• Distributor channels
• CDSCO approval routes
• Buyer audit qualification

Country Segment Breakdown Table

Segment	Sub-Segments
By Form	Powder · Crystalline
By Purity Grade	≥99.5% · 98.0% to 99.5% · <98%
By Application	Partial-Onset Seizures · Adjunctive Epilepsy Therapy
By Sales Channel	Direct · Distributors · Online/API Marketplaces
Key Sub-Regions Covered, API and Formulation Clusters	Hyderabad · Ahmedabad · western formulation clusters

Frequently Asked Questions

How fast is India lacosamide market growing?

India is projected to expand at 6.7% CAGR from 2026 to 2036. The outlook reflects the country-specific demand and sourcing profile.

Who leads India lacosamide market?

The validated regional companies are listed in the Key Companies section.

What is driving adoption in India lacosamide market?

Formulation approvals and API supply depth are projected to support India’s lacosamide demand profile.

How fast is the lacosamide market growing in China?

A 6.2% CAGR through 2036 reflects supply diversification and export documentation improvements.

Country Market Snapshot Table

Parameter	Value
Market Size in 2025 (Value)	USD 120.5 million
Market Size in 2026 (Value)	USD 128.0 million
Market Forecast in 2036 (Value)	USD 233.6 million
CAGR (2026 to 2036)	6.2%
Years Considered	2021 to 2036
Base Year	2025
Forecast Period	2026 to 2036
Units Considered	Value (USD million)
Leading Sub-Region	Jiangsu, Zhejiang, and Shandong API corridors

China Lacosamide Market Outlook

• China is commercially relevant through chemical synthesis scale and export-oriented API capacity. Overseas buyers treat documentation clarity as a decisive filter before adding China-based suppliers to approved vendor lists.
• Regulatory certificate rules are projected to support more structured export screening. Buyers still need plant audits and impurity trend files before a supplier change is approved.

Key Growth Drivers

• Export certificate pathways support international buyer screening. NMPA expanded certificate scope for GMP manufacturers in 2025.
• Policy clarity improves supplier comparison for products manufactured for overseas customers. NMPA stated export certificates can cover products not approved in China.
• Chemical synthesis capacity keeps China relevant for dual-source API programs.
• Buyer diversification programs create demand for alternate supply outside single-country sourcing.

Key Restraints

• Public lacosamide-specific approval evidence remains limited for some China-based suppliers.
• Overseas buyers may require additional audits before a China source is approved.
• Export certificate rules raise documentation expectations for suppliers that want regulated-market contracts.

What makes China unique

China is differentiated by supply diversification and export documentation beyond local therapy demand.

Key Companies

• Zhejiang Jiuzhou Pharmaceutical
• Hainan Poly Pharm
• Apeloa Pharmaceutical
• Shanghai Pharmaceuticals
• Zhejiang Hisun Pharmaceutical
• Shanghai Fosun Pharmaceutical

Sales & Marketing Channels

• Export API sales
• FDF export channels
• API trader networks
• CDMO partnerships
• NMPA documentation routes
• Buyer audit qualification

Country Segment Breakdown Table

Segment	Sub-Segments
By Form	Powder · Crystalline
By Purity Grade	≥99.5% · 98.0% to 99.5% · <98%
By Application	Partial-Onset Seizures · Adjunctive Epilepsy Therapy
By Sales Channel	Direct · Distributors · Online/API Marketplaces
Key Sub-Regions Covered, API and Formulation Clusters	Jiangsu · Zhejiang · Shandong API corridors

Frequently Asked Questions

How fast is China lacosamide market growing?

China is projected to expand at 6.2% CAGR from 2026 to 2036. The outlook reflects the country-specific demand and sourcing profile.

Who leads China lacosamide market?

The validated regional companies are listed in the Key Companies section.

What is driving adoption in China lacosamide market?

Supply diversification and export certificate clarity are projected to support China-based API sourcing.

What is the lacosamide market outlook in the United States?

A 5.2% CAGR through 2036 reflects ANDA activity and broad oral and injectable product listings.

Country Market Snapshot Table

Parameter	Value
Market Size in 2025 (Value)	USD 323.2 million
Market Size in 2026 (Value)	USD 340.0 million
Market Forecast in 2036 (Value)	USD 564.5 million
CAGR (2026 to 2036)	5.2%
Years Considered	2021 to 2036
Base Year	2025
Forecast Period	2026 to 2036
Units Considered	Value (USD million)
Leading Sub-Region	New Jersey, North Carolina, and national ANDA sponsor networks

United States Lacosamide Market Outlook

• The United States remains the reference market for lacosamide API qualification with FDA product records influencing buyer acceptance globally. Finished-dose sponsors need suppliers that can answer quality questions quickly.
• Generic price pressure keeps API sourcing cost-sensitive. Buyers still reject low-cost suppliers that cannot support impurity data and post-approval change control.

Key Growth Drivers

• Generic entry supports API pull-through across tablets and solutions. FDA analysis placed lacosamide tablet savings at USD 2,246 million.
• Product visibility supports supplier qualification across formats. DailyMed records list oral and injectable lacosamide products.
• Hospital injectable use gives qualified suppliers an added route into acute-care formularies.
• Direct ANDA sponsor relationships help API vendors manage document requests before source changes.

Key Restraints

• Generic prices reduce supplier margin flexibility. FDA reported a 92% decline in lacosamide tablet prices after first generic approval.
• Post-approval source changes can require time-consuming ANDA updates.
• CMS reported prescription drug spending rose 7.9% in 2024, keeping affordability under public payer review.

What makes United States unique

The United States is differentiated by FDA-listed products that influence supplier acceptance across several export markets.

Key Companies

• UCB Inc.
• Aucta Pharmaceuticals
• Cambrex
• Glenmark Pharmaceuticals Inc., USA
• Amneal Pharmaceuticals
• Camber Pharmaceuticals
• Fresenius Kabi USA

Sales & Marketing Channels

• ANDA sponsor relationships
• Generic distributor networks
• Hospital injectable channels
• DMF support routes
• Wholesaler channels
• Pharmacy channels

Country Segment Breakdown Table

Segment	Sub-Segments
By Form	Powder · Crystalline
By Purity Grade	≥99.5% · 98.0% to 99.5% · <98%
By Application	Partial-Onset Seizures · Adjunctive Epilepsy Therapy
By Sales Channel	Direct · Distributors · Online/API Marketplaces
Key Sub-Regions Covered, API and Formulation Clusters	New Jersey · North Carolina · national ANDA sponsor networks

Frequently Asked Questions

How fast is United States lacosamide market growing?

United States is projected to expand at 5.2% CAGR from 2026 to 2036. The outlook reflects the country-specific demand and sourcing profile.

Who leads United States lacosamide market?

The validated companies are listed in the Key Companies section.

What is driving adoption in United States lacosamide market?

ANDA activity and product listings are projected to keep USA supplier qualification central to global demand.

How fast is the lacosamide market growing in South Korea?

A 5.0% CAGR through 2036 reflects regulated generic access and reimbursement-based buyer behavior.

Country Market Snapshot Table

Parameter	Value
Market Size in 2025 (Value)	USD 34.3 million
Market Size in 2026 (Value)	USD 36.0 million
Market Forecast in 2036 (Value)	USD 58.6 million
CAGR (2026 to 2036)	5.0%
Years Considered	2021 to 2036
Base Year	2025
Forecast Period	2026 to 2036
Units Considered	Value (USD million)
Leading Sub-Region	Seoul capital region and domestic hospital channels

South Korea Lacosamide Market Outlook

• South Korea has a regulated generic structure that ties medicine access to approval and reimbursement. Buyers prefer suppliers that can provide complete technical files and stable batch records.
• Domestic demand is projected to remain smaller than the United States or China. Supplier credibility still carries value by reducing approval risk and supporting reimbursement continuity.

Key Growth Drivers

• MFDS review coverage creates demand for well-documented API sources. The approval process covers pharmaceutical ingredients under Article 31.
• Generic drug review supports buyers that need complete evidence packages. MFDS classifies generic drugs within drug product approval routes.
• Hospital neurology channels influence branded and generic prescribing for seizure control products.
• Reimbursement-based supply encourages buyers to prioritize quality records over opportunistic switching.

Key Restraints

• Smaller market scale limits room for many API suppliers.
• Reimbursed drug management can raise documentation expectations for generics and supply stability.
• Public evidence for country-specific lacosamide API sourcing remains limited in open records.

What makes South Korea unique

South Korea is differentiated by commercial uptake tied to reimbursement status and regulatory confidence.

Key Companies

• Hyundai Pharm
• Whanin Pharm
• SK Chemicals

Sales & Marketing Channels

• Domestic generic channels
• Hospital pharmacy channels
• Wholesaler networks
• MFDS approval routes
• Distributor import channels
• Buyer audit qualification

Country Segment Breakdown Table

Segment	Sub-Segments
By Form	Powder · Crystalline
By Purity Grade	≥99.5% · 98.0% to 99.5% · <98%
By Application	Partial-Onset Seizures · Adjunctive Epilepsy Therapy
By Sales Channel	Direct · Distributors · Online/API Marketplaces
Key Sub-Regions Covered, API and Formulation Clusters	Seoul capital region and domestic hospital channels

Frequently Asked Questions

How fast is South Korea lacosamide market growing?

South Korea is projected to expand at 5.0% CAGR from 2026 to 2036. The outlook reflects the country-specific demand and sourcing profile.

Who leads South Korea lacosamide market?

The validated regional companies are listed in the Key Companies section.

What is driving adoption in South Korea lacosamide market?

MFDS review expectations and reimbursement control are projected to shape supplier selection in South Korea.

How fast is the lacosamide market growing in Germany?

A 4.9% CAGR through 2036 reflects supply reliability needs under reimbursement pressure.

Country Market Snapshot Table

Parameter	Value
Market Size in 2025 (Value)	USD 78.2 million
Market Size in 2026 (Value)	USD 82.0 million
Market Forecast in 2036 (Value)	USD 132.3 million
CAGR (2026 to 2036)	4.9%
Years Considered	2021 to 2036
Base Year	2025
Forecast Period	2026 to 2036
Units Considered	Value (USD million)
Leading Sub-Region	North Rhine-Westphalia and national pharmacy tender networks

Germany Lacosamide Market Outlook

• Germany treats antiseizure medicines as supply-sensitive products with therapy interruption creating clinical risk. API buyers focus on continuity and regulatory readiness before accepting supplier changes.
• Tender systems keep price pressure high across generic medicines. Suppliers with clean inspection histories and reliable delivery records should hold better positions in long-term agreements.

Key Growth Drivers

• Supply relevance status raises attention to continuity and alternate sourcing. BfArM lists lacosamide within supply-relevant active substances.
• Manufacturing indicators support supplier monitoring. Destatis reported order stocks rose 0.4% in April 2026.
• Pharmacy substitution keeps chronic therapy products in organized distribution routes.
• Tender-backed purchasing favors API suppliers with predictable change-control files.

Key Restraints

• Reference pricing limits finished-dose margin and API pricing flexibility.
• Manufacturing order softness can affect buyer confidence. Destatis reported new orders fell 3.8% in April 2026.
• Supply disruption reporting can damage supplier trust quickly in chronic therapy categories.

What makes Germany unique

Germany is differentiated by sourcing decisions that weigh continuity alongside acquisition cost.

Key Companies

• Neuraxpharm
• Aristo Pharma
• STADA Arzneimittel
• Ratiopharm
• Hexal
• Accord Healthcare Germany

Sales & Marketing Channels

• Generic tender channels
• Wholesaler networks
• Hospital pharmacy channels
• Regulatory dossier routes
• Pharmacy benefit channels
• Specialist distributor channels

Country Segment Breakdown Table

Segment	Sub-Segments
By Form	Powder · Crystalline
By Purity Grade	≥99.5% · 98.0% to 99.5% · <98%
By Application	Partial-Onset Seizures · Adjunctive Epilepsy Therapy
By Sales Channel	Direct · Distributors · Online/API Marketplaces
Key Sub-Regions Covered, API and Formulation Clusters	North Rhine-Westphalia and national pharmacy tender networks

Frequently Asked Questions

How fast is Germany lacosamide market growing?

Germany is projected to expand at 4.9% CAGR from 2026 to 2036. The outlook reflects the country-specific demand and sourcing profile.

Who leads Germany lacosamide market?

The validated regional companies are listed in the Key Companies section.

What is driving adoption in Germany lacosamide market?

Supply relevance and tender purchasing are projected to guide German lacosamide sourcing. Pharmacy continuity adds another selection filter.

How fast is the lacosamide market growing in United Kingdom?

A 4.8% CAGR through 2036 reflects oral liquid authorization and pharmacy continuity needs.

Country Market Snapshot Table

Parameter	Value
Market Size in 2025 (Value)	USD 64.9 million
Market Size in 2026 (Value)	USD 68.0 million
Market Forecast in 2036 (Value)	USD 108.7 million
CAGR (2026 to 2036)	4.8%
Years Considered	2021 to 2036
Base Year	2025
Forecast Period	2026 to 2036
Units Considered	Value (USD million)
Leading Sub-Region	London, Midlands, and NHS pharmacy corridors

United Kingdom Lacosamide Market Outlook

• The United Kingdom has a controlled-access structure for lacosamide API demand through prescription medicines. Oral liquid availability keeps dosing flexibility relevant alongside tablet-based therapy.
• NHS cost control limits premium capture but supports consistent generic use. API suppliers need authorization-holder relationships and reliable document support to remain qualified.

Key Growth Drivers

• Oral liquid authorization supports API demand for flexible dosing. MHRA granted Lacosamide Novumgen at 10 mg/mL.
• Product record depth supports supplier visibility. MHRA product data lists 435 lacosamide files.
• Community pharmacy continuity supports demand from oral solution suppliers.
• Direct relationships with authorization holders help API vendors handle variation questions.

Key Restraints

• NHS pricing controls limit room for suppliers to recover costs after tender pressure.
• Prescription-only classification narrows casual channel access for oral solution products.
• Supplier changes can slow for buyers that prefer stable chemistry records.

What makes United Kingdom unique

The United Kingdom is differentiated by pharmacy continuity and payer discipline in supplier decisions.

Key Companies

• Accord Healthcare
• Glenmark Pharmaceuticals Europe
• Novumgen Limited
• Aurobindo Pharma
• Neuraxpharm UK
• Teva UK
• UCB Pharma Limited

Sales & Marketing Channels

• MAH direct sales
• Specialist distributors
• Hospital pharmacy routes
• NHS procurement channels
• Community pharmacy routes
• Regulatory support routes

Country Segment Breakdown Table

Segment	Sub-Segments
By Form	Powder · Crystalline
By Purity Grade	≥99.5% · 98.0% to 99.5% · <98%
By Application	Partial-Onset Seizures · Adjunctive Epilepsy Therapy
By Sales Channel	Direct · Distributors · Online/API Marketplaces
Key Sub-Regions Covered, API and Formulation Clusters	London · Midlands · NHS pharmacy corridors

Frequently Asked Questions

How fast is United Kingdom lacosamide market growing?

United Kingdom is projected to expand at 4.8% CAGR from 2026 to 2036. The outlook reflects the country-specific demand and sourcing profile.

Who leads United Kingdom lacosamide market?

The validated companies are listed in the Key Companies section.

What is driving adoption in United Kingdom lacosamide market?

Prescription medicine authorization and pharmacy continuity are projected to support controlled UK growth.

How fast is the lacosamide market growing in France?

A 4.6% CAGR through 2036 reflects generic use under close regulator oversight.

Country Market Snapshot Table

Parameter	Value
Market Size in 2025 (Value)	USD 61.2 million
Market Size in 2026 (Value)	USD 64.0 million
Market Forecast in 2036 (Value)	USD 100.3 million
CAGR (2026 to 2036)	4.6%
Years Considered	2021 to 2036
Base Year	2025
Forecast Period	2026 to 2036
Units Considered	Value (USD million)
Leading Sub-Region	Île-de-France and national pharmacy distribution channels

France Lacosamide Market Outlook

• France shows API demand sensitivity to product-level regulatory action despite available therapeutic alternatives. Buyers evaluate dossier risk carefully before changing API sources.
• Pharmacy-level continuity and reimbursement pressure keep the growth profile cautious. Suppliers with inspection-ready files can gain trust from authorization holders and distributors.

Key Growth Drivers

• Multiple tablet strengths sustain manufacturing needs across dose ranges. ANSM listed four Lacosamide EG tablet strengths in its product review.
• Regulatory oversight reinforces demand for audit-ready supplier records. ANSM action covered seven marketing authorizations.
• Generic substitution supports steady API demand through national pharmacy distribution.
• Substitutable products reduce dependence on a single supplier or one finished-dose route.

Key Restraints

• Product-level suspensions can trigger buyer reviews of supplier and dossier risk.
• ANSM reported pharmacy-level recalls for affected suspended medicines, raising continuity risk for buyers.
• Reimbursement pressure narrows the room for higher-cost API inputs.

What makes France unique

France is differentiated by pharmacy-level continuity controls that convert product reviews into sourcing decisions.

Key Companies

• Biogaran
• EG Labo
• Sandoz France
• Teva Santé
• Viatris Santé
• Zentiva France
• Arrow Génériques
• Zydus France

Sales & Marketing Channels

• MAH direct sales
• Wholesaler networks
• Hospital supply routes
• Generic substitution channels
• Pharmacovigilance channels
• Pharmacy distribution routes

Country Segment Breakdown Table

Segment	Sub-Segments
By Form	Powder · Crystalline
By Purity Grade	≥99.5% · 98.0% to 99.5% · <98%
By Application	Partial-Onset Seizures · Adjunctive Epilepsy Therapy
By Sales Channel	Direct · Distributors · Online/API Marketplaces
Key Sub-Regions Covered, API and Formulation Clusters	Île-de-France and national pharmacy distribution channels

Frequently Asked Questions

How fast is France lacosamide market growing?

France is projected to expand at 4.6% CAGR from 2026 to 2036. The outlook reflects the country-specific demand and sourcing profile.

Who leads France lacosamide market?

The validated companies are listed in the Key Companies section.

What is driving adoption in France lacosamide market?

Generic substitution and regulator scrutiny are projected to keep France focused on clean supplier records.

How fast is the lacosamide market growing in Japan?

A 4.4% CAGR through 2036 reflects cautious source switching and high documentation expectations.

Country Market Snapshot Table

Parameter	Value
Market Size in 2025 (Value)	USD 70.9 million
Market Size in 2026 (Value)	USD 74.0 million
Market Forecast in 2036 (Value)	USD 113.8 million
CAGR (2026 to 2036)	4.4%
Years Considered	2021 to 2036
Base Year	2025
Forecast Period	2026 to 2036
Units Considered	Value (USD million)
Leading Sub-Region	Tokyo, Osaka, and specialist hospital corridors

Japan Lacosamide Market Outlook

• Japan has a quality-sensitive structure in which regulator updates can shape product review after approval. Buyers prioritize proven quality systems and stable supply over frequent source changes.
• Demand is projected to grow more slowly than in emerging supplier markets. API vendors need Japanese documentation readiness and clean inspection histories to enter approved supply chains.

Key Growth Drivers

• Safety label monitoring keeps lacosamide visible in regulated medicine channels. PMDA listed lacosamide oral dosage form in FY2025 revisions.
• Precaution documentation supports product review discipline. PMDA posted a lacosamide precaution file of 26.5 KB.
• Specialist neurology prescribing supports stable demand for seizure control products.
• High-quality documentation needs support premium supplier qualification.

Key Restraints

• Conservative buyer behavior slows adoption of new API sources.
• Regulatory documentation burden can raise supplier entry costs.
• PMDA safety information No. 428 reinforces the need for close precaution monitoring.

What makes Japan unique

Japan is differentiated by supplier credibility that can outweigh short-term price advantage in approval-based sourcing.

Key Companies

• UCB Japan
• Daiichi Sankyo
• Sawai Pharmaceutical
• Towa Pharmaceutical
• Nissin Pharmaceutical
• Takata Pharmaceutical
• Kyowa Pharmaceutical Industry

Sales & Marketing Channels

• Marketing authorization channels
• Trading house sourcing
• Hospital specialist networks
• PMDA documentation routes
• Generic pharmacy channels
• Wholesaler networks

Country Segment Breakdown Table

Segment	Sub-Segments
By Form	Powder · Crystalline
By Purity Grade	≥99.5% · 98.0% to 99.5% · <98%
By Application	Partial-Onset Seizures · Adjunctive Epilepsy Therapy
By Sales Channel	Direct · Distributors · Online/API Marketplaces
Key Sub-Regions Covered, API and Formulation Clusters	Tokyo · Osaka · specialist hospital corridors

Frequently Asked Questions

How fast is Japan lacosamide market growing?

Japan is projected to expand at 4.4% CAGR from 2026 to 2036. The outlook reflects the country-specific demand and sourcing profile.

Who leads Japan lacosamide market?

The validated regional companies are listed in the Key Companies section.

What is driving adoption in Japan lacosamide market?

PMDA precaution review and conservative source switching are projected to shape Japan’s lacosamide sourcing.

Who are the leading companies in the lacosamide market?

MSN Laboratories and Cambrex show visible API evidence. Aurobindo and Dr. Reddy’s add finished-dose reach. UCB and Daiichi Sankyo provide originator and regional product evidence.

• API suppliers compete through impurity control depth and pharmacopoeial coverage. Regulatory document support remains a key selection filter.
• Finished-dose sponsors influence API demand through tablets and oral solutions. Injectable listings add another pull-through route.
• Integrated generics companies gain an advantage by connecting API sourcing with approved product portfolios.
• Specialist suppliers can win second-source programs by reducing audit friction and batch-change risk.

Competition in lacosamide API is shaped by evidence depth and not only price. MSN Laboratories lists lacosamide among its world generics examples and reports broad API capacity. Smaller suppliers need faster technical support and clean batch histories. Buyers judge suppliers by their ability to support approved products and reduce regulatory questions. This logic mirrors buyer discipline in branded generics procurement.

Capability depth is visible across specialist supplier pages and regulator product listings. Cambrex identifies lacosamide as an anti-epileptic API with CAS 175481-36-4. SNJ Labs lists Lacosamide USP/EP/BP under anticonvulsants and marks GMP status. API suppliers also need downstream awareness with fill finish manufacturing and oral-liquid requirements affect buyer qualification work.

Companies with multi-format evidence are better positioned to serve regulated buyers. Integrated sponsors extend API pull-through through approved finished-dose products. Rakshit Drugs and SNJ Labs remain relevant for buyers that need dedicated API support. Suppliers that understand pharmaceutical packaging expectations can also support oral solution and injectable product readiness.

How do top lacosamide companies compare?

MSN Laboratories and Cambrex focus strongly on regulatory file support. Aurobindo and Dr. Reddy’s add dosage-form relevance.

Company	Impurity Control Depth	Dosage-Form Support	Regulatory File Support	Channel Reach	Geographic Footprint
MSN Laboratories	Very Strong	Strong	Very Strong	Strong	India and global exports
Cambrex	Very Strong	Strong	Very Strong	Strong	Europe and North America
Rakshit Drugs	Strong	Moderate	Strong	Moderate	India and export markets
SNJ Labs	Moderate	Moderate	Strong	Moderate	India and export markets
Zhejiang Jiuzhou Pharmaceutical	Strong	Moderate	Strong	Moderate	China and export markets
Hainan Poly Pharm	Moderate	Very Strong	Strong	Strong	China and United States
Aurobindo Pharma	Strong	Very Strong	Very Strong	Very Strong	Global
Dr. Reddy’s Laboratories	Strong	Very Strong	Very Strong	Very Strong	Global
Glenmark Pharmaceuticals	Strong	Strong	Strong	Strong	Global
Accord Healthcar	Moderate	Strong	Strong	Strong	Europe and United Kingdom

Source: Future Market Insights competitive analysis, 2026.

Who are the key players in the lacosamide market?

The profiled companies combine API suppliers and finished-dose sponsors listed below.

Key global companies leading the lacosamide market include:

• MSN Laboratories
• Cambrex
• Rakshit Drugs
• SNJ Labs
• Zhejiang Jiuzhou Pharmaceutical
• Hainan Poly Pharm
• Aurobindo Pharma
• Dr. Reddy’s Laboratories
• Glenmark Pharmaceuticals
• Accord Healthcare
• UCB
• Daiichi Sankyo

Key Developments in Lacosamide Market

• In January 2024, Aurobindo Pharma received an FDA Orange Book listing for lacosamide oral solution 10 mg/mL. This added another oral liquid route for generic buyers.
• In May 2024, Novumgen received UK authorization for Lacosamide Novumgen 10 mg/mL syrup. This supported oral liquid availability in the United Kingdom.
• In November 2025, CDSCO recommended permission for Intas to manufacture and market lacosamide injection. This added India evidence for injectable formulation activity.

Key Players in the Lacosamide Market

Integrated Generic Sponsors

• Aurobindo Pharma
• Dr. Reddy’s Laboratories
• Glenmark Pharmaceuticals
• Accord Healthcare
• Hikma
• Amneal Pharmaceuticals
• Camber Pharmaceuticals

API and Drug Substance Suppliers

• MSN Laboratories
• Cambrex
• Rakshit Drugs
• SNJ Labs
• Zhejiang Jiuzhou Pharmaceutical
• Apeloa Pharmaceutical

Specialist and Newer Product Participants

• Hainan Poly Pharm
• UCB
• Daiichi Sankyo
• SK Chemicals
• Whanin Pharm
• Torrent Pharmaceuticals
• Novumgen Limited

Lacosamide Market - Scope & Definition

Attribute	Detail
Market Definition	Commercially traded lacosamide active pharmaceutical ingredient used in tablets, oral solutions, and injectable preparations for epilepsy therapy.
Functions Covered	Drug substance supply, impurity control, formulation input, regulatory file support, and dosage-form qualification.
Applications Covered	Partial-onset seizure therapy and adjunctive epilepsy therapy in approved oral and injectable products.
End-Use Industries	Generic pharmaceutical manufacturing, hospital injectable supply chains, API distribution, and regulated formulation manufacturing.
Grades Covered	≥99.5%, 98.0% to 99.5%, and <98% purity grades.
Inclusions	Lacosamide API in powder and crystalline forms sold through direct supplier contracts, distributors, and online/API marketplaces.
Exclusions	Finished branded medicine sales, patient dispensing revenue, unrelated anticonvulsant APIs, veterinary products, and non-pharmaceutical intermediates.

Lacosamide Market - Research Methodology

Method	Description
Primary Research	FMI analyst interviews with API buyers, generic formulation firms, regulatory consultants, distributors, and quality teams serving epilepsy product portfolios.
Desk Research	Review of drug labels, regulatory approval records, official company API pages, pharmacopoeial references, and public agency publications.
Market Sizing & Forecasting	Bottom-up API volume assumptions were combined with formulation conversion rates, regional price bands, purity requirements, and country approval activity.
Data Validation	Forecasts were cross-verified against tablet, oral solution, and injectable demand patterns along with supplier portfolios and regulator listings.

Lacosamide Market - Report Scope

Parameter	Details
Forecast period	2026 to 2036
Historical period	2021 to 2025
Quantitative unit	Revenue in USD million
By form	Powder, crystalline
By purity grade	≥99.5%, 98.0% to 99.5%, <98%
By application	Partial-onset seizures, adjunctive epilepsy therapy
By sales channel	Direct, distributors, online/API marketplaces
Regions covered	North America, Latin America, Europe, East Asia, South Asia and Pacific, Middle East and Africa
Countries covered	India, China, United States, South Korea, Germany, United Kingdom, France, Japan
Key companies profiled	MSN Laboratories, Cambrex, Rakshit Drugs, SNJ Labs, Zhejiang Jiuzhou Pharmaceutical, Hainan Poly Pharm, Aurobindo Pharma, Dr. Reddy’s Laboratories, Glenmark Pharmaceuticals, Accord Healthcare, UCB, Daiichi Sankyo
Approach	Hybrid bottom-up and top-down methodology using product approvals, API supplier evidence, country demand signals, and segment-level adoption assumptions

Lacosamide Market Breakdown by Form, Purity Grade, Application, Sales Channel, and Region

Lacosamide Market Segmented by Form

• Powder
• Crystalline

Lacosamide Market Segmented by Purity Grade

• ≥99.5%
• 98.0% to 99.5%
• <98%

Lacosamide Market Segmented by Application

• Partial-Onset Seizures
• Adjunctive Epilepsy Therapy

Lacosamide Market Segmented by Sales Channel

• Direct
• Distributors
• Online/API Marketplaces

Lacosamide Market by Region

• North America
• Latin America
• Europe
• East Asia
• South Asia and Pacific
• Middle East and Africa

Research Sources and Bibliography

• USA Food and Drug Administration. (2024, September). Estimating cost savings from new generic drug approvals in 2022. FDA.
• Centers for Medicare & Medicaid Services. (2026, January 14). NHE fact sheet. CMS.
• USA National Library of Medicine. (2026, February). Lacosamide tablet, film coated. DailyMed.
• USA National Library of Medicine. (2026, June). Lacosamide injection. DailyMed.
• USA Food and Drug Administration. (2024, January). Orange Book cumulative supplement, January 2024. FDA.
• Medicines and Healthcare products Regulatory Agency. (2024, May 31). Marketing authorisations granted 15 to 31 May 2024. MHRA.
• Medicines and Healthcare products Regulatory Agency. (2026, June). Lacosamide substance product records. MHRA Products.
• Bundesinstitut für Arzneimittel und Medizinprodukte. (2024, December). Liste versorgungsrelevanter Wirkstoffe nach §52b Abs. 3c AMG. BfArM.
• Federal Statistical Office of Germany. (2026, June 18). Stock of orders in manufacturing in April 2026. Destatis.
• Agence nationale de sécurité du médicament et des produits de santé. (2026, June 5). Synapse Labs: nous nous prononçons sur les autorisations de mise sur le marché de certains médicaments. ANSM.
• Pharmaceuticals and Medical Devices Agency. (2025, June 24). Revisions of precautions FY2025. PMDA.
• Pharmaceuticals and Medical Devices Agency. (2026, April). Pharmaceuticals and medical devices safety information No. 428. PMDA.
• National Medical Products Administration. (2025, December 24). Policy interpretation of the national medical products export certificate measures. NMPA.
• Central Drugs Standard Control Organisation. (2025, November 11). Recommendations of SEC Neurology and Psychiatry. CDSCO.
• Central Drugs Standard Control Organisation. (2026, April 23). Recommendations of SEC Neurology and Psychiatry. CDSCO.
• MSN Laboratories. (2026, June). Active pharmaceutical ingredients. MSN Laboratories.
• Cambrex. (2026, June). Lacosamide API products. Cambrex.
• SNJ Labs. (2026, June). Anticonvulsants: Lacosamide. SNJ Labs.
• Torrent Pharmaceuticals. (2026, June). Product prescribing information for Lacosam. Torrent Pharmaceuticals.
• Base de Données Publique des Médicaments. (2026, June). Lacosamide Biogaran product record. Government of France.
• Ministry of Health, Labour and Welfare. (2026, June 11). National Health Insurance drug price listing codes. MHLW.
• Korea Pharmaceutical Information Center. (2026, June). Neopat Tab lacosamide product identification. KPIC.
• SK Chemicals. (2026, June). Vimsk lacosamide-based anticonvulsant. SK Chemicals.
• Accord Healthcare. (2025, April). Lacosamide tablets products database. Accord Healthcare.
• Hainan Poly Pharm. (2026, June). Lacosamide injection label. DailyMed.
• Apeloa Pharmaceutical. (2025, November). API product catalogue including lacosamide. Apeloa Pharmaceutical.
• Shanghai Pharmaceuticals Holding Co., Ltd. (2024, April). Annual report product approvals including lacosamide oral solution and injection. Shanghai Pharmaceuticals.
• Hyundai Pharm. (2026, June). Central nervous system product list including lacosamide. Hyundai Pharm.
• Whanin Pharm. (2026, June). Lacosamide product listing for Neopat tablets. Korea Pharmaceutical Information Center.

This bibliography is provided for reader reference. It uses primary regulatory and company-published sources tied to report claims.

This Report Answers

• The report explains the current and projected value of the lacosamide market from 2026 to 2036.
• The report identifies the CAGR forecast for lacosamide API demand across the assessment period.
• The report explains which form is projected to lead lacosamide API purchasing in 2026.
• The report assesses why the ≥99.5% purity grade carries higher commercial weight for regulated buyers.
• The report evaluates how oral and injectable formats shape lacosamide API demand.
• The report compares country-level growth across eight profiled markets.
• The report profiles suppliers and finished-dose companies with visible lacosamide evidence.
• The report explains buyer risks that shape supplier qualification in lacosamide API sourcing.
• The report defines market inclusions and exclusions for lacosamide API analysis.
• The report describes how FMI validates lacosamide API forecasts using source triangulation and buyer interviews.
• The report evaluates competitive positioning across API suppliers and integrated generic sponsors.
• The report provides market data and supporting analysis in a structured Word format.